Clinical TrialsThe James Cancer Center Columbus, OH
open for enrollment
Safety and Efficacy of Entospletinib With Vincristine and Dexamethasone in Adults With Relapsed or Refractory Acute Lymphoid Leukemia (ALL)
A Phase Ib/II, Open-Label, Dose Escalation and Expansion Study Evaluating the Safety and Efficacy of Entospletinib (GS-9973) with Vincristine and Dexamethasone in Adult Subjects with Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL)
This study will evaluate the safety, efficacy, tolerability, and pharmacokinetics of
entospletinib (GS-9973) in combination with vincristine (VCR), and dexamethasone in adults
with previously treated relapsed or refractory B-cell lineage acute lymphoid leukemia (ALL).
This study consists of two parts: Dose Escalation and Dose Expansion. After 2 induction
cycles during either parts of the study, participants may be put on maintenance for up to 36
cycles if they have obtained clinical benefit from the treatment.
Are you eligible?
Adults with ALL in need of treatment
Diagnosis of Burkitt's Leukemia, or lymphoid blast crisis of chronic myelogenous
History of myelodysplastic syndrome or solid organ transplantation
Prior allogeneic bone marrow progenitor cell transplant within 100 days or on active
immunosuppression for graft versus host disease (GVHD) treatment or prophylaxis
within 28 days prior to enrollment